Treatment Workflow Study Comparing Intravenous and Subcutaneous Administration of Isatuximab for Multiple Myeloma Treatment: Understanding Impact on Healthcare Resource Utilization from HCPs' Perspective

Treatment Workflow Study Comparing Intravenous and Subcutaneous Administration of Isatuximab for Multiple Myeloma Treatment: Understanding Impact on Healthcare Resource Utilization from HCPs' Perspective - Treatment Workflow Study Comparing Intravenous and Subcutaneous Administration of Isatuximab for Multiple Myeloma Treatment: Understanding Impact on Healthcare Resource Utilization from HCPs' Perspective

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000058306

Enrollment

Registered

2025-06-27

Start date

2025-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple myeloma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: [Physicians] Physicians who meet all of the following inclusion criteria will be included: 1_Belongs to the department of hematology 2_Decides treatment for multiple myeloma on their own 3_Has been involved in the treatment (such as prescription) with intravenous (IV) injectables for multiple myeloma patients 4_Has been involved in the treatment (such as prescription) with subcutaneous (SC) injectables (isatuximab) for multiple myeloma patients 5_Agreed to participate in this survey [Nurses] Nurses who meet all of the following inclusion criteria will be included: 1_Has been involved in multiple myeloma treatment 2_Has been involved in the treatment (such as administration) with IV injectables for multiple myeloma patients (not limited to clinical trials) 3_Has been involved in the treatment (such as administration) with SC injectables (isatuximab) for multiple myeloma patients 4_Agreed to participate in the survey [Pharmacists] Pharmacists who meet all of the following inclusion criteria will be included: 1_Has dispensed IV injections for the treatment of multiple myeloma at least once (not limited to clinical trials) 2_Has been involved in multiple myeloma treatment (such as dispensation of the drug and medical supplies) with SC injectables (isatuximab) 3_Agreed to participate in this survey

Exclusion criteria

Exclusion criteria: Not applicable

Design outcomes

Primary

Measure	Time frame
To evaluate the burden of physicians, nurses, pharmacists regarding subcutaneous (SC)/intravenous (IV) injectables for multiple myeloma treatment, specifically focusing on "administration of SC (OBI)/SC (manual) /IV injectable" and "post-treatment drug administration and monitoring" from their perspectives. _Burden of SC (OBI)/SC (manual)/IV administration *HCP's (physicians, nurses, pharmacists) capability of doing any other tasks and the burden on a patient during the process of the administrations of SC (OBI)/SC (manual) /IV injections for the treatment of multiple myeloma. The evaluation questioner consists of "administration of SC (OBI)/SC (manual) /IV injectable" and "post-treatment drug administration and monitoring". OBI: on-body injector	—

Measure

Time frame

To evaluate the burden of physicians, nurses, pharmacists regarding subcutaneous (SC)/intravenous (IV) injectables for multiple myeloma treatment, specifically focusing on "administration of SC (OBI)/SC (manual) /IV injectable" and "post-treatment drug administration and monitoring" from their perspectives. _Burden of SC (OBI)/SC (manual)/IV administration *HCP's (physicians, nurses, pharmacists) capability of doing any other tasks and the burden on a patient during the process of the administrations of SC (OBI)/SC (manual) /IV injections for the treatment of multiple myeloma. The evaluation questioner consists of "administration of SC (OBI)/SC (manual) /IV injectable" and "post-treatment drug administration and monitoring". OBI: on-body injector

—

Secondary

Measure	Time frame
To evaluate the time required by physicians, nurses, and pharmacists regarding subcutaneous (SC)/intravenous (IV) injectables for multiple myeloma treatment, specifically focusing on "administration of SC (OBI)/SC (manual) /IV injectable" and "post-treatment drug administration and monitoring" from their perspectives. _Time required for SC (OBI)/SC (manual) /IV administration among physicians, nurses, and pharmacists The average time required for the steps include "administration of SC (OBI)/SC (manual) /IV injectable" and "post-treatment drug administration and monitoring". To evaluate the current awareness in HCPs (physicians, nurses, pharmacists) from their perspectives regarding the use of SC/IV injectables in multiple myeloma treatment. _Benefits of and issues with SC/IV administration perceived by physicians, nurses, and pharmacists Evaluate the questions regarding the administrations of SC/IV injections in the treatment of multiple myeloma on a five-point scale of agreement or disagreement OBI: on-body injector	—

Measure

Time frame

To evaluate the time required by physicians, nurses, and pharmacists regarding subcutaneous (SC)/intravenous (IV) injectables for multiple myeloma treatment, specifically focusing on "administration of SC (OBI)/SC (manual) /IV injectable" and "post-treatment drug administration and monitoring" from their perspectives. _Time required for SC (OBI)/SC (manual) /IV administration among physicians, nurses, and pharmacists *The average time required for the steps include "administration of SC (OBI)/SC (manual) /IV injectable" and "post-treatment drug administration and monitoring". To evaluate the current awareness in HCPs (physicians, nurses, pharmacists) from their perspectives regarding the use of SC/IV injectables in multiple myeloma treatment. _Benefits of and issues with SC/IV administration perceived by physicians, nurses, and pharmacists *Evaluate the questions regarding the administrations of SC/IV injections in the treatment of multiple myeloma on a five-point scale of agreement or disagreement OBI: on-body injector

—

Countries

Japan

Contacts

Public ContactTomoyuki Kusaka

Social Survey Research Information Co., Ltd. Healthcare Business Intelligence

HOR@ssri.com03-6709-9710

Outcome results